SCHEMBL752673

SCHEMBL752673

Cc1ccccsc(C)c(C)c1C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.41
ACHE P22303 2/20 0.41
TRPA1 O75762 1/20 0.36
ATM Q13315 1/20 0.36
GAA P10253 2/20 0.35
ALDH1A1 P00352 8/20 0.34
PKM P14618 2/20 0.34
SMN1; SMN2 Q16637 5/20 0.33
RAB9A P51151 4/20 0.33
TP53 P04637 2/20 0.33
MAPT P10636 2/20 0.33
HSD17B10 Q99714 2/20 0.33
KDM4E B2RXH2 2/20 0.33
CYP2A6 P11509 2/20 0.33
ALOX15 P16050 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
CTNNB1 P35222 1/20 0.33
WNT3A P56704 1/20 0.33
CA1 P00915 1/20 0.33
CA2 P00918 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Water SCHEMBL5196978 0.98 TSHR (0.39) TSHRACHETRPA1ATMGAA
Hydrochloric Acid SCHEMBL154108 0.98 TSHR (0.39) TSHRACHETRPA1ATMGAA
Hydrochloric Acid SCHEMBL31150435 0.98 TSHR (0.39) TSHRACHETRPA1ATMGAA
Hydrochloric Acid SCHEMBL3327763 0.96 TSHR (0.38) TSHRACHETRPA1ATMGAA
SCHEMBL753567 0.91 TSHR (0.41) TSHRACHETRPA1ATMGAA
Water SCHEMBL28584406 0.88 TSHR (0.39) TSHRACHETRPA1ATMGAA
Hydrochloric Acid SCHEMBL4373437 0.88 TSHR (0.39) TSHRACHETRPA1ATMGAA
Sulfuric Acid SCHEMBL2110043 0.88 GAA (0.36) TSHRACHETRPA1ATMGAA
Formic Acid SCHEMBL5197972 0.88 ALDH1A1 (0.36) TSHRACHETRPA1ATMGAA
Acetic Acid SCHEMBL5196852 0.88 GAA (0.40) TRPA1GAAALDH1A1PKMSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2431359-B1 Process for preparing diaminophenothiazinium compounds PROVEPHARM LIFE SOLUTIONS (FR) 2020-06-03 EP claimed
EP-2046767-B1 PROCESS FOR PREPARING DIAMINOPHENOTHIAZINIUM COMPOUNDS PROVENCE TECHNOLOGIES (FR) 2015-04-22 EP claimed
US-20150056160-A1 CHEMICALLY INDUCED INTRACELLULAR HYPERTHERMIA TEXAS PHARMACEUTICALS, INC. 2015-02-26 US claimed
CN-102596967-A Photochemical process for producing artemisinin SANOFI AVENTIS 2012-07-18 CN claimed
EP-2431359-A1 Process for preparing diaminophenothiazinium compounds Provence Technologies (FR) 2012-03-21 EP claimed
US-20100056643-A1 CHEMICALLY INDUCED INTRACELLULAR HYPERTHERMIA ST. JUDE PHARMACEUTICALS, INC. 2010-03-04 US claimed
EP-2046767-A2 PROCESS FOR PREPARING DIAMINOPHENOTHIAZINIUM COMPOUNDS Provence Technologies (FR) 2009-04-15 EP claimed
WO-2008006979-A2 PROCESS FOR PREPARING DIAMINOPHENOTHIAZINIUM COMPOUNDS PROVENCE TECHNOLOGIES (FR) 2008-01-17 WO claimed
EP-1647543-B1 A method for inhibiting polymerization of (Meth) acrylic acid and its esters using an inhibitor and a process for making a compound useful as such an inhibitor ROHM & HAAS (US) 2007-05-02 EP claimed
EP-1098641-A4 CHEMICALLY INDUCED INTRACELLULAR HYPERTHERMIA ST JUDE PHARMACEUTICALS INC (US) 2003-08-27 EP claimed
EP-1098641-A1 CHEMICALLY INDUCED INTRACELLULAR HYPERTHERMIA Texas Pharmaceuticals, Inc. (US) 2001-05-16 EP claimed
WO-2000006143-A1 CHEMICALLY INDUCED INTRACELLULAR HYPERTHERMIA TEXAS PHARMACEUTICALS, INC. (US) 2000-02-10 WO claimed
EP-2913327-B1 Methylene blue and its medical use PROVEPHARM LIFE SOLUTIONS (FR) 2023-06-07 EP disclosed
CN-105683389-B Method for specifically labeling live bacteria comprising use of modified monosaccharide compounds 国家科学研究中心 2021-09-28 CN disclosed
EP-2431359-B1 Process for preparing diaminophenothiazinium compounds PROVEPHARM LIFE SOLUTIONS (FR) 2020-06-03 EP disclosed
CN-107848992-A Method for chemically synthesizing substituted 10H-phenothiazine-3, 7-diamine compound 维斯塔实验室有限公司 2018-03-27 CN disclosed
US-20060074257-A1 Method for inhibiting polymerization of (meth)acrylic acid and its esters using an inhibitor and a process for making a compound useful as such an inhibitor BASS STEPHEN 2006-04-06 US disclosed
EP-1098641-A4 CHEMICALLY INDUCED INTRACELLULAR HYPERTHERMIA ST JUDE PHARMACEUTICALS INC (US) 2003-08-27 EP disclosed
EP-1098641-A1 CHEMICALLY INDUCED INTRACELLULAR HYPERTHERMIA Texas Pharmaceuticals, Inc. (US) 2001-05-16 EP disclosed
WO-2000006143-A1 CHEMICALLY INDUCED INTRACELLULAR HYPERTHERMIA TEXAS PHARMACEUTICALS, INC. (US) 2000-02-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060074257-A1 Method for inhibiting polymerization of (meth)acrylic acid and its esters using an inhibitor and a process for making a compound useful as such an inhibitor MMAB, AZI2, MEP1A TSHR 4161/4885ACHE 1933/4885TRPA1 4343/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.